MedTrace Logo

Domperidone and the Risk of Serious Adverse Events

NCT07098078 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2025-08-01

No results posted yet for this study

Summary

This study will assess whether initiating domperidone at doses ≥30 mg/day compared to \<30 mg/day in patients with advanced chronic kidney disease (CKD) (estimated glomerular filtration rate \[eGFR\] \<45 mL/min/1.73 m² but not receiving dialysis) is associated with a higher 30-day risk of a composite outcome of all-cause hospitalization or all-cause emergency visits or all-cause mortality.

Conditions

  • Chronic Kidney Disease (CKD)

Interventions

DRUG

Domperidone (drug)

The primary exposure of interest will be oral domperidone at a dose of 30 mg or more per day, which represents the median dose found in high-throughput computing analyses. For the primary comparison, oral domperidone at doses below 30 mg per day will be chosen to reduce the influence of indication bias.

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Amit Garg · London Health Sciences Centre Research Institute

Eligibility

Min Age
66 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-01
Primary Completion
2024-09-30
Completion
2024-10-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07098078 on ClinicalTrials.gov